Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


deltaDOT Ltd receives £3 million from investors

London, UK, 1 October 2007…. deltaDOT Ltd, a developer of innovative molecular imaging technologies and products for bioscience research and biological production, today announced that it has received £3 million in a fourth and final tranche of funding from the investors in its last private equity financing round, following the continuing success of the business. This brings the total raised in the round to £6 million ($12.1 million).

The funding round, which was announced in March 2006, comprised a syndicate of investors including FF&P Private Equity, Imperial Innovations, NPI Ventures, Sitka Health Fund VCT and London Technology Fund. FF&P Private Equity, the private equity division of Fleming Family & Partners (FF&P), acted as lead investor.

Anthony Baxter, CEO of deltaDOT said: “This funding highlights the success of deltaDOT and our recent corporate deals. We are already achieving our sales targets for Peregrine, our High Throughput Capillary Electrophoresis systems, and the funds raised will enable us to increase the production capacity for our Peregrine system. We will also develop our international sales and marketing function, particularly in the USA, which has already been expanded with a number of recent appointments to the board of directors and management team.” The funding will also be used to continue to develop a number of other capillary and microfluidic products for molecular imaging, in particular the Osprey protein unfolding instrument which is set to improve on current thermal analysis of proteins currently employed by Differential Scanning Calorimetry (DSC) and Isothermal Titration Calorimetry (ITC).

deltaDOT’s products make use of a novel biomolecule detection technique called Label Free Intrinsic Imaging (LFIITM). This applies innovations in high-energy physics research to biochemical analysis. Unlike conventional techniques, the technology does not require target molecules to be labelled and enables superior data quantification, while reducing throughput times and operating costs.

deltaDOT recently announced that the company is playing a key role in a US Defence Advanced Research Projects Agency (DARPA) funded project to develop technology and processes that will reduce the time it takes to manufacture vaccines and protein therapeutics, to enhance the response to a wide range of biological threats. deltaDOT’s Peregrine High Performance Capillary Electrophoresis and Osprey protein stability technology platforms are being used to analyse product quality in a cost-effective manner throughout product development, from the R&D to the quality control stages. The consortium of four companies, which is led by Xcellerex Inc (Marlborough, MA), received a total of US$7.9 million from the Agency.

- ENDS -

Publisher Contact Information:

deltaDOT Ltd
+44 (0)207 594 1001

Company profile of deltaDOT Ltd
Past press releases of deltaDOT Ltd.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 21€87.0MInternet services
Feb 21€18.0MInternet commerce
Feb 20€4.3MSoftware development
Feb 19€0.4MInternet commerce
Feb 19€8.4MMedical devices
Feb 18€25.0MBiotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.